- Regulatory T-cell (Treg) level is an independent predictor of OS and PFS with stereotactic ablative radiotherapy (SABR) for pulmonary recurrence-based oligometastatic NSCLC.
Why this matters
- Patients with high pretreatment Treg levels may need other treatments in addition to SABR.
- Prospective study of 63 patients with pulmonary recurrence-based oligometastatic NSCLC receiving SABR (66.7% men; median age, 63 [range, 44-84] years).
- Median follow-up was 19.1 months.
- Funding: National Key Research and Development Program of China; Shandong Key Research and Development Program; National Natural Science Foundation of China.
- Estimated OS rates at 1, 2, and 3 years were 84.3%, 63.4%, and 44.0%, respectively.
- Corresponding PFS rates were 55.2%, 30.9%, and 25.7%.
- Patients with high Treg levels had poorer OS (16.1 months vs not reached; P=.006) and PFS (11.0 vs 21.7 months; P=.013).
- Multivariate analyses confirmed Treg level as an independent predictor of both OS (HR, 2.68; P=.038) and PFS (HR, 2.35; P=.011).
- Small sample size.
- Tumor histology varied across patients.
- Potential misclassification of second primary cancer as recurrent disease.